| 4 |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
| 324K |
| $30.0M |
| 0.0% |
| 4.833% |
| 0.31% |
| 5 | Saturn V Capital Management LP | 312K | $28.9M | -9.7% | 4.657% | 4.14% |
| 6 | Siren, L.L.C. | 270K | $25.0M | 0.0% | 4.032% | 0.51% |
| 7 | ADAR1 Capital Management, LLC | 218K | $20.1M | -17.7% | 3.248% | 0.92% |
| 8 | Polar Capital Holdings Plc | 214K | $19.9M | -5.3% | 3.202% | 0.05% |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 210K | $19.4M | -4.0% | 3.131% | 0.00% |
| 10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 209K | $19.4M | -32.3% | 3.123% | 0.03% |
| 11 | TCG Crossover Management, LLC | 203K | $18.8M | +53.9% | 3.035% | 0.45% |
| 12 | WELLINGTON MANAGEMENT GROUP LLP | 158K | $14.7M | -9.1% | 2.365% | 0.00% |
| 13 | ORBIMED ADVISORS LLC | 157K | $14.6M | — | 2.350% | 0.27% |
| 14 | Candriam S.C.A. | 143K | $13.3M | — | 2.140% | 0.06% |
| 15 | BALYASNY ASSET MANAGEMENT L.P. | 135K | $12.5M | -1.4% | 2.008% | 0.02% |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 113K | $10.4M | +12.7% | 1.681% | 0.00% |
| 17 | Alyeska Investment Group, L.P. | 100K | $9.3M | 0.0% | 1.493% | 0.02% |
| 18 | STATE STREET CORP | 93K | $8.6M | +4.8% | 1.382% | 0.00% |
| 19 | Vivo Capital, LLC | 91K | $8.4M | 0.0% | 1.351% | 0.77% |
| 20 | DRIEHAUS CAPITAL MANAGEMENT LLC | 84K | $7.8M | +153.5% | 1.255% | 0.05% |
| 21 | Bank of New York Mellon Corp | 77K | $7.1M | -2.1% | 1.149% | 0.00% |
| 22 | Vestal Point Capital, LP | 76K | $7.0M | +15.8% | 1.130% | 0.16% |
| 23 | Longaeva Partners L.P. | 56K | $5.2M | — | 0.834% | 0.11% |
| 24 | Neuberger Berman Group LLC | 55K | $5.1M | +30.1% | 0.824% | 0.00% |
| 25 | MILLENNIUM MANAGEMENT LLC | 50K | $4.7M | -5.0% | 0.751% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in MNPR — a direct measure of their conviction.
| 47.29% |
| +4.96 pp |
| $109M |
| +91% |
| Q4 2024 | 19 | +171% | 42.33% | +41.88 pp | $57M | +53861% |
| Q3 2024 | 7 | — | 0.45% | — | $0M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
27 institutions opened new positions in MNPR during Q2 2026, while 14 fully exited. 58 added to existing positions and 8 trimmed.
MNPR institutional ownership fell by 0.39 percentage points quarter-over-quarter, with a net change of +13 holders.
The top 10 institutions account for 65.8% of all reported 13F value in MNPR, and the top 25 account for 91.4%.
Across the largest Rare Disease Biotech peers, institutional ownership levels are: IRLA (23.9%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.